Temsirolimus, an inhibitor of mammalian target of rapamycin kinase, has anti-proliferative and anti-angiogenic properties. Encouraging results were seen in phase I and II studies of temsirolimus ...

This phase I study was conducted to determine the maximum tolerated dose of temsirolimus and sunitinib when given in combination to patients with advanced RCC. The study population consisted of ...

Am J Health Syst Pharm. 2010;67(24):2095-2106. Temsirolimus is primarily metabolized by the cytochrome P-450 (CYP) 3A4 isoenzyme to five major metabolites, with sirolimus being the principal ...